Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.

The Journal of pathology - 1 Dec 2001

Gnanasampanthan G, Elsaleh H, McCaul K, Iacopetta B

Abstract excerpt

Ki-ras mutations are associated with an increased risk of relapse and death in colorectal cancer (CRC) patients, with some mutations being more aggressive than others. The present study examined the predictive value of different Ki-ras mutation types in a retrospective series of 430 Dukes' C stage CRC patients, of whom 208 (48%) had received adjuvant chemotherapy with 5-fluorouracil/levamisole or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Aspartic Acid
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Genes, ras

Share to Patient Selection

Share to Regression Analysis

Share to Survival Rate

Source

Identifiers

PMID: 11745689
DOI: 10.1002/path.990

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.PMID 11745689Read ↗

Distinctive clinicopathological features of Ki-ras mutated colorectal cancers.Semantic proximity Read ↗

Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.Semantic proximity Read ↗

The type of K-ras mutation determines prognosis in colorectal cancer.Semantic proximity Read ↗

Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.Semantic proximity Read ↗

Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortalitySemantic proximity Read ↗

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.Semantic proximity Read ↗

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.Semantic proximity Read ↗

Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292)Semantic proximity Read ↗

Is K-ras Gene Mutation a Prognostic Factor for Colorectal CancerSemantic proximity Read ↗

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.Semantic proximity Read ↗

Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer.Semantic proximity Read ↗

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.